BioAtla Files $200M Mixed Securities Shelf
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy BCAB?
BioAtla files $200M mixed securities shelf
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCAB
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.190
Low
10.00
Averages
10.00
High
10.00
Current: 0.190
Low
10.00
Averages
10.00
High
10.00
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
- Funding Support: BioAtla secures an initial $5 million through a SPV transaction with GATC Health for general operations and Phase 2+ OPSCC clinical trial expenses, with an additional $35 million expected to close in Q1 2026, ensuring liquidity for Oz-V's development.
- Equity Structure: Following the SPV transaction, BioAtla will retain 65% ownership of Oz-V while Inversagen AI will acquire a 35% stake, optimizing capital allocation and laying the groundwork for future commercialization.
- Clinical Trial Advancement: BioAtla will lead the Phase 3 trial for Oz-V in OPSCC, with enrollment anticipated to begin in early 2026, and potential accelerated approval could significantly enhance market opportunities, particularly in HPV-positive tumors.
- Technical Collaboration: The partnership with Inversagen AI will advance the research and development of CAB senolytic therapies, with BioAtla maintaining exclusive rights for cancer therapeutic applications, thereby strengthening its technological capabilities and supporting its long-term strategic positioning in the anti-aging sector.
See More
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
- Funding Support: BioAtla secures an initial $5 million through a SPV transaction with GATC Health for Oz-V's operational and clinical trial expenses, with an additional $35 million expected to close in Q1 2026, ensuring progress in the 2L+ OPSCC development.
- Equity Structure: After the SPV transaction, BioAtla will retain 65% ownership of Oz-V, maintaining its leading position across all solid tumor indications, while Inversagen AI will acquire a 35% stake, fostering collaborative research on age-related diseases.
- Clinical Trial Plans: BioAtla will lead the Phase 3 trial for Oz-V in OPSCC, with enrollment anticipated to begin in early 2026, paving the way for potential accelerated approval and significantly enhancing the company's competitiveness in the oncology market.
- Market Potential: Targeting the ROR2 receptor, Oz-V has the potential to expand into HPV-positive tumors, representing a market opportunity exceeding $7 billion, while BioAtla's CAB platform technology is poised to play a crucial role in treating age-related diseases, further solidifying its market position.
See More
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
- Funding Support: BioAtla secures an initial $5 million through a SPV transaction with GATC Health for general operations and Phase 2+ OPSCC clinical trial expenses, with an additional $35 million expected to close in Q1 2026, ensuring liquidity for Oz-V's development.
- Equity Structure: Following the SPV transaction, BioAtla will retain 65% ownership of Oz-V while Inversagen AI will acquire a 35% stake, optimizing capital allocation and laying the groundwork for future commercialization.
- Clinical Trial Advancement: BioAtla will lead the Phase 3 trial for Oz-V in OPSCC, with enrollment anticipated to begin in early 2026, and potential accelerated approval could significantly enhance market opportunities, particularly in HPV-positive tumors.
- Technical Collaboration: The partnership with Inversagen AI will advance the research and development of CAB senolytic therapies, with BioAtla maintaining exclusive rights for cancer therapeutic applications, thereby strengthening its technological capabilities and supporting its long-term strategic positioning in the anti-aging sector.
See More
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
- Funding Support: BioAtla secures an initial $5 million through a SPV transaction with GATC Health for Oz-V's operational and clinical trial expenses, with an additional $35 million expected to close in Q1 2026, ensuring progress in the 2L+ OPSCC development.
- Equity Structure: After the SPV transaction, BioAtla will retain 65% ownership of Oz-V, maintaining its leading position across all solid tumor indications, while Inversagen AI will acquire a 35% stake, fostering collaborative research on age-related diseases.
- Clinical Trial Plans: BioAtla will lead the Phase 3 trial for Oz-V in OPSCC, with enrollment anticipated to begin in early 2026, paving the way for potential accelerated approval and significantly enhancing the company's competitiveness in the oncology market.
- Market Potential: Targeting the ROR2 receptor, Oz-V has the potential to expand into HPV-positive tumors, representing a market opportunity exceeding $7 billion, while BioAtla's CAB platform technology is poised to play a crucial role in treating age-related diseases, further solidifying its market position.
See More
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
See More
